(Post-pandemic Era)-Global Duchenne Muscular Dystrophy Therapeutics Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2015-2026
- Report Code : XYZ2132237
- Published On: Nov, 2020
- Category : Machinery & Equipment
- Pages : 104
-
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Research team published a report for global Duchenne Muscular Dystrophy Therapeutics market in this environment.
In terms of revenue, this research report indicated that the global Duchenne Muscular Dystrophy Therapeutics market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of Duchenne Muscular Dystrophy Therapeutics industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Bristol-Myers Squibb Company aims at producing XX Duchenne Muscular Dystrophy Therapeutics in 2020, with XX % production to take place in global market, FibroGen accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Duchenne Muscular Dystrophy Therapeutics Market Include by
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Duchenne Muscular Dystrophy Therapeutics Market
Bristol-Myers Squibb Company
FibroGen
ITALFARMACO
Marathon Pharmaceuticals
NS Pharma
PTC Therapeutics
Pfizer
ReveraGen BioPharma
Santhera Pharmaceuticals
Sarepta Therapeutics
Major Type of Duchenne Muscular Dystrophy Therapeutics Covered in report:
Pain Management Drugs
Corticosteroids
Prednisolone
Prednisone
Deflazacort
Application Segments Covered in report
Hospitals
Clinics
Home Care Settings
For any other requirements, please feel free to contact us and we will provide you customized report.
-
With tables and figures helping analyze worldwide (Post pandemic Era) Global Duchenne Muscular Dystrophy Therapeutics market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.
Global Duchenne Muscular Dystrophy Therapeutics Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope1.1 Product Details and Introduction
1.1.1 Pain Management Drugs -Product Introduction and Major Manufacturers
1.1.2 Corticosteroids -Product Introduction and Major Manufacturers
1.1.3 Prednisolone -Product Introduction and Major Manufacturers
1.1.4 Prednisone -Product Introduction and Major Manufacturers
1.1.5 Deflazacort -Product Introduction and Major Manufacturers1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Duchenne Muscular Dystrophy Therapeutics Market Assessment, by Segmentation2.1 Type Breakdown Estimates & Forecast, Sales Volume (2015-2026)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2015-2026)
2.3 Application Breakdown Estimates & Forecast, by Application (2015-2026)
3 Regional Market Analysis3.1 China Duchenne Muscular Dystrophy Therapeutics Market
3.1.1 Top Companies leading Duchenne Muscular Dystrophy Therapeutics Development in China (2015-2020)
3.1.2 Sales Value of Major Company in China Market (2015-2020)
3.1.3 China Duchenne Muscular Dystrophy Therapeutics Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2015-2026)3.2 EU Duchenne Muscular Dystrophy Therapeutics Market
3.2.1 Top Companies leading Duchenne Muscular Dystrophy Therapeutics Development in EU (2015-2020)
3.2.2 Sales Value of Major Company in EU Market (2015-2020)
3.2.3 EU Duchenne Muscular Dystrophy Therapeutics Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2015-2026)3.3 USA Duchenne Muscular Dystrophy Therapeutics Market
3.3.1 Top Companies leading Duchenne Muscular Dystrophy Therapeutics Development in USA (2015-2020)
3.3.2 Sales Value of Major Company in USA Market (2015-2020)
3.3.3 USA Duchenne Muscular Dystrophy Therapeutics Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2015-2026)3.4 Japan Duchenne Muscular Dystrophy Therapeutics Market
3.4.1 Top Companies leading Duchenne Muscular Dystrophy Therapeutics Development in Japan (2015-2020)
3.4.2 Sales Value of Major Company in Japan Market (2015-2020)
3.4.3 Japan Duchenne Muscular Dystrophy Therapeutics Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2015-2026)3.5 India Duchenne Muscular Dystrophy Therapeutics Market
3.5.1 Top Companies leading Duchenne Muscular Dystrophy Therapeutics Development in India (2015-2020)
3.5.2 Sales Value of Major Company in India Market (2015-2020)
3.5.3 India Duchenne Muscular Dystrophy Therapeutics Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2015-2026)3.6 Southeast Asia Duchenne Muscular Dystrophy Therapeutics Market
3.6.1 Top Companies leading Duchenne Muscular Dystrophy Therapeutics Development in Southeast Asia (2015-2020)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2015-2020)
3.6.3 Southeast Asia Duchenne Muscular Dystrophy Therapeutics Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2015-2026)
3.7 South America Duchenne Muscular Dystrophy Therapeutics Market
3.7.1 Top Companies leading Duchenne Muscular Dystrophy Therapeutics Development in South America (2015-2020)
3.7.2 Sales Value of Major Company in South America Market (2015-2020)
3.7.3 South America Duchenne Muscular Dystrophy Therapeutics Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2015-2026)
4 Value Chain (Impact of COVID-19)4.1 Duchenne Muscular Dystrophy Therapeutics Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream4.2 COVID-19 Impact on Duchenne Muscular Dystrophy Therapeutics Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2026)5.1 Global Duchenne Muscular Dystrophy Therapeutics Sales and Growth Rate (2021-2026)
5.2 Global Duchenne Muscular Dystrophy Therapeutics Sales Value and Growth Rate (2021-2026)
6 Duchenne Muscular Dystrophy Therapeutics Competitive Analysis6.1 Bristol-Myers Squibb Company
6.1.1 Bristol-Myers Squibb Company Company Profiles
6.1.2 Bristol-Myers Squibb Company Product Introduction
6.1.3 Bristol-Myers Squibb Company Duchenne Muscular Dystrophy Therapeutics Production, Revenue (2015-2020)
6.1.4 SWOT Analysis6.2 FibroGen
6.2.1 FibroGen Company Profiles
6.2.2 FibroGen Product Introduction
6.2.3 FibroGen Duchenne Muscular Dystrophy Therapeutics Production, Revenue (2015-2020)
6.2.4 SWOT Analysis6.3 ITALFARMACO
6.3.1 ITALFARMACO Company Profiles
6.3.2 ITALFARMACO Product Introduction
6.3.3 ITALFARMACO Duchenne Muscular Dystrophy Therapeutics Production, Revenue (2015-2020)
6.3.4 SWOT Analysis6.4 Marathon Pharmaceuticals
6.4.1 Marathon Pharmaceuticals Company Profiles
6.4.2 Marathon Pharmaceuticals Product Introduction
6.4.3 Marathon Pharmaceuticals Duchenne Muscular Dystrophy Therapeutics Production, Revenue (2015-2020)
6.4.4 SWOT Analysis6.5 NS Pharma
6.5.1 NS Pharma Company Profiles
6.5.2 NS Pharma Product Introduction
6.5.3 NS Pharma Duchenne Muscular Dystrophy Therapeutics Production, Revenue (2015-2020)
6.5.4 SWOT Analysis6.6 PTC Therapeutics
6.6.1 PTC Therapeutics Company Profiles
6.6.2 PTC Therapeutics Product Introduction
6.6.3 PTC Therapeutics Duchenne Muscular Dystrophy Therapeutics Production, Revenue (2015-2020)
6.6.4 SWOT Analysis
6.7 Pfizer
6.7.1 Pfizer Company Profiles
6.7.2 Pfizer Product Introduction
6.7.3 Pfizer Duchenne Muscular Dystrophy Therapeutics Production, Revenue (2015-2020)
6.7.4 SWOT Analysis
6.8 ReveraGen BioPharma
6.8.1 ReveraGen BioPharma Company Profiles
6.8.2 ReveraGen BioPharma Product Introduction
6.8.3 ReveraGen BioPharma Duchenne Muscular Dystrophy Therapeutics Production, Revenue (2015-2020)
6.8.4 SWOT Analysis
6.9 Santhera Pharmaceuticals
6.9.1 Santhera Pharmaceuticals Company Profiles
6.9.2 Santhera Pharmaceuticals Product Introduction
6.9.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Therapeutics Production, Revenue (2015-2020)
6.9.4 SWOT Analysis6.10 Sarepta Therapeutics
6.10.1 Sarepta Therapeutics Company Profiles
6.10.2 Sarepta Therapeutics Product Introduction
6.10.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Therapeutics Production, Revenue (2015-2020)
6.10.4 SWOT Analysis
7 Conclusion
-
The (Post pandemic Era) Global Duchenne Muscular Dystrophy Therapeutics Market has been segregated into various crucial divisions including applications, types, and regions. Each market segment is intensively studied in the report contemplating its market acceptance, worthiness, demand, and growth prospects. The segmentation analysis will help the client to customize their marketing approach to have a better command of each segment and to identify the most prospective customer base.
Report Objectives / Segmentation Covered :
By Companies / players:
By Regions:
By Type:
By Application:
Frequently asked questions(FAQ's):
New players are entering the (Post pandemic Era) Global Duchenne Muscular Dystrophy Therapeutics Market, while established companies are changing their business models and strategies. This pattern is likely to continue for the foreseeable future.
(Post pandemic Era) Global Duchenne Muscular Dystrophy Therapeutics has a wide range of applications, including
The (Post pandemic Era) Global Duchenne Muscular Dystrophy Therapeutics Market study evaluates the year spans as follows: Historical year: 2019 to 2024; Base year: 2024; Forecast period**: 2025 to 2030 [** unless otherwise stated]
As the shift to value addition continues, companies in the (Post pandemic Era) Global Duchenne Muscular Dystrophy Therapeutics Market face the dual challenge of improving interoperability to optimize performance and experience.
The (Post pandemic Era) Global Duchenne Muscular Dystrophy Therapeutics Market is expected to reach a considerable market valuation.
